Stockscreener 앱 받기
3.94
4.18%
0.11
Kodiak Sciences Inc 주식(KOD)의 최신 뉴스
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion - The Globe and Mail
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? - Yahoo Finance
Millennium Management LLC Cuts Holdings in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Kodiak Sciences Q2 EPS Forecast Decreased by Zacks Research - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Position Increased by Public Employees Retirement System of Ohio - Defense World
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Kodiak Sciences Holds 2025 Annual Stockholders Meeting - TipRanks
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare C - GuruFocus
Kodiak Sciences Reveals Latest Retinal Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads - Investing.com Australia
Kodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroads By Investing.com - Investing.com India
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
Kodal Minerals Nears Export Permit For Mali Lithium Project - Finimize
Kodiak Sciences Inc Reports Q1 2025 Earnings: EPS of -$1.09 Misses Estimates, No Revenue Reported - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress - GuruFocus
KOD Plans to Unveil Key Developments as Phase 3 Trials Progress | KOD Stock News - GuruFocus
Kodiak Sciences Announces Recent Business Highlights and First Q - GuruFocus
Kodiak Sciences Reports Deeper Q1 Loss: What 3 Key Phase 3 Trials Mean for Future Growth - Stock Titan
Kodiak Sciences (KOD) Projected to Post Earnings on Wednesday - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Dimensional Fund Advisors LP - Defense World
MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - The AM Reporter
MetLife Investment Management LLC Invests $209,000 in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wells Fargo & Company MN Sells 2,710 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Ratio Review: Analyzing Kodiak Sciences Inc (KOD)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Retinal vein occlusion Market: Epidemiology, Therapies, - openPR.com
BlackRock, Inc. Reduces Stake in Kodiak Sciences Inc. - GuruFocus
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatilit - GuruFocus
CND Life Sciences Closes $13.5M Series A Equity Round to Continue Growth and Innovation in Neurodiagnostics - The Malaysian Reserve
Breakthrough Eye Disease Platform: Kodiak Sciences Reveals 7 Major Advances at ARVO 2025 - Stock Titan
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases - Yahoo Finance
Wet Age-Related Macular Degeneration Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight - Barchart.com
JPMorgan Chase & Co. Increases Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc [KOD] Shares Rise 9.62 % on Wednesday - knoxdaily.com
A year in review: Kodiak Sciences Inc (KOD)’s performance in the last year - uspostnews.com
Insider’s View: Deciphering Kodiak Sciences Inc (KOD)’s Financial Health Through Ratios - DWinneX
April 2025's Promising Penny Stocks - Yahoo
AMKR Shares Experience Decline in Value - knoxdaily.com
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
Why Coffee Prices Remain Volatile - The Globe and Mail
Prudential Financial Inc. Sells 65,400 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Wet Age-Related Macular Degeneration Therapeutics Market Size - openPR.com
Sei Investments Co. Sells 69,599 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences stock hits 52-week low at $2.15 - Investing.com India
HC Wainwright Comments on Kodiak Sciences Q2 Earnings - Defense World
HC Wainwright Forecasts Kodiak Sciences Q1 Earnings - Defense World
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) - Yahoo Finance
0.34%
7.69%
자본화:
|
볼륨(24시간):